The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report
Thrombotic microangiopathy (TMA) has different etiological causes, and not all of them are well understood. In atypical hemolytic uremic syndrome (aHUS), the TMA is caused by the complement dysregulation associated with pathogenic mutations in complement components and its regulators. Here, we descr...
Main Authors: | Javier Lumbreras, Marta Subias, Natalia Espinosa, Juana María Ferrer, Emilia Arjona, Santiago Rodríguez de Córdoba |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01348/full |
Similar Items
-
Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
by: Romy N. Bouwmeester, et al.
Published: (2021-01-01) -
Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS
by: Elisabetta Valoti, et al.
Published: (2019-05-01) -
Favorable course of previously undiagnosed Methylmalonic Aciduria with Homocystinuria (cblC type) presenting with pulmonary hypertension and aHUS in a young child: a case report
by: Luciano De Simone, et al.
Published: (2018-08-01) -
Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)—Two Diseases That Exacerbate Each Other: Case Report
by: Anna Bogdał, et al.
Published: (2021-08-01) -
Atypical hemolytic uremic syndrome: a brief review
by: Kuixing Zhang, et al.
Published: (2017-06-01)